ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F

Also written as “AZD0120”, “GC012F Injection” and “AZD0120 - Regimen 1”.

Its studies are mostly in Multiple Myeloma · Lupus Erythematosus, Systemic · Immunoglobulin Light-chain Amyloidosis · Multiple Sclerosis · Scleroderma, Systemic, led by AstraZeneca.

Drug pageAutologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F: every studyAll 29 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jan 30, 202612 company-led studies, 12 open or runningNext primary completion: Feb 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca1212 open or runningphase 3since Jan 30, 2026Apr 18, 2023Feb 1, 2027phase 2 · NCT06530849
  • Named in AstraZeneca’s own pipeline as AZD0120, phase 3, as of Oct 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 18, 2023First study: phase 2 study in Multiple MyelomaFirst studyNCT05850234 · 232 planned · United States
  2. Jan 23, 2024Phase 2 study in Multiple MyelomaNCT06235229 · 110 planned · China
  3. Jul 25, 2024Phase 2 study in Lupus Erythematosus, SystemicNCT06530849 · 20 enrolled · China
  4. Mar 12, 2025Phase 2 study in Lupus Erythematosus, SystemicNCT06897930 · 150 planned · United States, Australia, Canada and more
  5. Jul 7, 2025Phase 2 study in Immunoglobulin Light-chain AmyloidosisNCT07081646 · 91 planned · United States, Canada, United Kingdom
  6. Jul 10, 2025Phase 1 study in Multiple MyelomaNCT07073547 · 40 planned · United States
  7. Oct 16, 2025Phase 2 study in Scleroderma, SystemicNCT07295847 · 27 planned · United States, Australia, Germany and more
  8. Oct 21, 20252 phase 1 studiesNCT07250269, NCT07224373
  9. Jan 30, 2026Phase 3 study in Multiple MyelomaPhase 3 reachedNCT07391657 · 508 planned · United States, Australia, Brazil and more
  10. Jul 1, 20262 phase 3 studies in Multiple MyelomaNCT07764978, NCT07735637
  11. Oct 21, 2026Primary completion moved from 2028-10-11 to 2028-11-02Date moved laterphase 3 · +1 months · NCT07735637

Ahead

  1. Feb 1, 2027Primary completion: phase 2 study in Lupus Erythematosus, SystemicNCT06530849
  2. Oct 1, 2027Primary completion: phase 2 study in Multiple MyelomaNCT05850234
  3. Feb 22, 2028Primary completion: phase 2 study in Scleroderma, SystemicNCT07295847
  4. May 26, 2028Primary completion: phase 1 study in Multiple MyelomaNCT07073547

TargetBeta

“A preparation of autologous T-lymphocytes engineered to express two separate chimeric antigen receptors (CARs) targeting the tumor-associated antigens (TAAs) BCMA and CD19 and fused to as of yet not fully elucidated co-stimulatory domains, with potential immunostimulating and antineoplastic activ…”NCIt, read by Claude
“A preparation of autologous T-lymphocytes engineered to express two separate chimeric antigen receptors (CARs) targeting the tumor-associated antigens (TAAs) BCMA and CD19 and ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
BCMA-CD19 Compound CAR T Cellsruleicell-gene-therapeuticsphase 13

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07735637Multiple Myeloma · United States, Australia, Brazil and more3RecruitingNov 2, 2028750
NCT07764978Multiple Myeloma · United States, Australia, Brazil and more3RecruitingJan 11, 2029750
NCT07391657Multiple Myeloma · United States, Australia, Brazil and more3RecruitingJun 14, 2028508
NCT07250269Immunoglobulin Light-chain Amyloidosis · China1RecruitingNov 24, 202812
NCT07224373Multiple Sclerosis · United States, Australia, Canada and more1RecruitingDec 12, 202824
NCT07295847Scleroderma, Systemic · United States, Australia, Germany and more2RecruitingFeb 22, 202827
NCT07073547Multiple Myeloma · United States1RecruitingMay 26, 202840
NCT07081646Immunoglobulin Light-chain Amyloidosis · United States, Canada, United Kingdom2RecruitingAug 15, 202991
NCT06897930Lupus Erythematosus, Systemic · United States, Australia, Canada and more2RecruitingMay 1, 2029150
NCT06530849Lupus Erythematosus, Systemic · China2Active, not recruitingFeb 1, 202720
NCT06235229Multiple Myeloma · China2RecruitingMar 2, 2026110
NCT05850234Multiple Myeloma · United States2RecruitingOct 1, 2027232

How it is read

Names in the registry

  • “AZD0120”, 8 entries
  • “GC012F Injection”, 2 entries
  • “AZD0120 - Regimen 1”, 1 entry
  • “AZD0120 - Regimen 2”, 1 entry
  • “GC012F”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.